You aren’t paying attention very well. A number of NICE reimbursement rejections have happened not because of a lack of effectiveness but rather because of cost issues. You must be aiming for a rejection from NICE due to cost issues as the basis for wanting NWBO to front run Flaskworks proof of concept and final price of treatment based more on that at a minimum. Don’t you ever listen to the complaints from Nemesis?; ). Best wishes.
Market Data 
Markets 
